BRIEF-Galmed Announces First Time Results In Oncology Studies Aramchol Significantly Enhances Bayer's Regorafenib Effect In Gi Cancer Models

Reuters
06 May
BRIEF-Galmed Announces First Time Results In Oncology Studies Aramchol Significantly Enhances Bayer's Regorafenib Effect In Gi Cancer Models

May 6 (Reuters) - Galmed Pharmaceuticals Ltd GLMD.O:

  • GALMED ANNOUNCES FIRST TIME RESULTS IN ONCOLOGY STUDIES: ARAMCHOL SIGNIFICANTLY ENHANCES BAYER'S REGORAFENIB EFFECT IN GI CANCER MODELS

  • GALMED PHARMACEUTICALS LTD - ARAMCHOL AND REGORAFENIB COMBINATION REDUCES TUMOR GROWTH IN MICE

  • GALMED PHARMACEUTICALS LTD - PHASE 1B STUDY OF ARAMCHOL AND REGORAFENIB TO START Q4 2025

Source text: ID:nPn4b7Hxka

Further company coverage: GLMD.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10